Back to Search
Start Over
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
- Source :
-
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2021 Nov; Vol. 19 (11), pp. 1277-1303. - Publication Year :
- 2021
-
Abstract
- Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation ("watch and wait") may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.
- Subjects :
- Adult
Humans
Prognosis
Erdheim-Chester Disease drug therapy
Hematologic Neoplasms
Histiocytosis, Langerhans-Cell diagnosis
Histiocytosis, Langerhans-Cell drug therapy
Histiocytosis, Langerhans-Cell pathology
Histiocytosis, Sinus diagnosis
Histiocytosis, Sinus drug therapy
Histiocytosis, Sinus pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1540-1413
- Volume :
- 19
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Journal of the National Comprehensive Cancer Network : JNCCN
- Publication Type :
- Academic Journal
- Accession number :
- 34781268
- Full Text :
- https://doi.org/10.6004/jnccn.2021.0053